In experimental cirrhosis and non-alcoholic fatty liver disease (NAFLD), farnesoid X receptor (FXR) agonists modulate the GVB to reduce bacterial translocation through driving β-catenin activation in endothelial cells (16, 17). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.